Blood-Based Sensor Detects Parkinson’s-Linked Proteins in 40 Minutes
At a Glance
- Researchers have developed a blood-based sensor to detect three forms of a protein linked to Parkinson’s disease.
- The transistor-based technology can measure the protein forms simultaneously in about 40 minutes.
- In an initial blinded evaluation, the platform achieved 90.9% accuracy.
- Researchers say larger studies are needed before the technology can be used as a routine clinical test.
Researchers at King Abdullah University of Science and Technology (KAUST) and the University of Oxford have developed a blood-based electronic sensor that detects three forms of alpha-synuclein associated with Parkinson’s disease in about 40 minutes, a potential advance in identifying disease-related changes through a blood sample.
Key Statements and Focus Area
- Detection technology: Researchers identified distinct patterns across the three forms of alpha-synuclein among the participant groups. They said measuring the forms together could provide more information than relying on a single marker.
- Early findings: "These early results are encouraging, and the next step is to validate the technology in much larger groups of patients." - KAUST Associate Professor of Bioengineering Sahika Inal
- Clinical limitations: The researchers said the platform is not yet a standalone diagnostic test and requires larger, prospective, multicenter studies.
The technology, described in the journal Science Advances, uses a transistor-based sensor to amplify biological signals and measure three forms of alpha-synuclein associated with Parkinson’s disease.
The process begins by isolating small packages released by nerve cells into the bloodstream. Researchers then analyze the proteins they contain, allowing the sensor to detect patterns linked to the disease.
Detecting alpha-synuclein in blood presents a challenge because more than 95% of circulating alpha-synuclein originates from red blood cells. This creates background interference that can make it difficult to identify signals associated with neurological conditions.
Initial Evaluation Shows Diagnostic Potential
In a blinded evaluation involving 59 participants from the Oxford Discovery cohort, the platform achieved 90.9% accuracy in distinguishing disease-associated profiles from those of healthy controls.
The group included people with Parkinson’s disease, healthy participants, and individuals with isolated rapid eye movement sleep behavior disorder, known as iRBD. The sleep disorder is associated with an increased risk of developing Parkinson’s and related neurological conditions.
Further Testing Needed
Sahika Inal said detecting blood-based changes associated with Parkinson’s remains difficult, particularly because these changes may occur before a clinical diagnosis.
The researchers cautioned that the findings represent an early evaluation rather than evidence that the technology is ready for routine diagnosis. The study was retrospective and involved an initial cohort, meaning the platform’s performance and predictive value must be assessed in larger prospective studies across multiple clinical centers.
FYI
Parkinson’s disease is a progressive neurological disorder that affects movement and can cause symptoms including tremors, stiffness, and slowed movement. Diagnosis currently relies largely on clinical assessment, making research into reliable biological markers an important area of investigation.
Alpha-synuclein is a protein found in nerve cells. Abnormal forms and accumulation of the protein are associated with Parkinson’s and some other neurological disorders. A blood-based method that reliably identifies disease-related patterns could eventually support earlier assessment, but the new sensor has not yet been established as a routine clinical diagnostic tool.
Dive Deeper: Handpicked Stories for You
Follow Channel8 for continuous updates:
Reducing Ultra-Processed Foods Linked to Improved Depression Symptoms
2 hours ago